Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
View Patent ↗The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.
1. An isolated nucleic acid comprising the nucleotide sequences shown by SEQ ID NO:2, SEQ ID NO:5, and SEQ ID NO:6;
provided that, if the nucleic acid is a DNA, the nucleotide symbol “u” in the sequence listings shall be replaced with “t”.
2. An isolated nucleic acid comprising the nucleotide sequence represented by SEQ ID NO:2;
provided that, if the nucleic acid is a DNA, the nucleotide symbol “u” in the sequence listing shall be replaced with “t”.
3. An isolated nucleic acid comprising the nucleotide sequence represented by SEQ ID NO:6;
provided that, if the nucleic acid is a DNA, the nucleotide symbol “u” in the sequence listing shall be replaced with “t”.
4. A replicon RNA comprising an RNA comprising the nucleotide sequences shown by SEQ ID NO:2, SEQ ID NO:5, and SEQ ID NO:6, wherein SEQ ID NO: 5 is located at the most 5′ end and 5′ in relation to SEQ ID NO: 2 and SEQ ID NO: 6 is located at the most 3′ end and 3′ in relation to SEQ ID NO:2.
5. The replicon RNA according to claim 4 , further comprising an IRES sequence.
6. The replicon RNA according to claim 5 , further comprising a selection marker gene or a reporter gene.
7. A replicon-replicating cell created by introducing the replicon RNA according to claim 4 into isolated cells.
8. The replicon-replicating cell according to claim 7 , wherein the isolated cells are human liver-derived cells, human cervix-derived cells, or human embryonic kidney-derived cells.
9. A method for screening for the ability of a substance to stimulate or suppress replication of hepatitis C virus, comprising culturing the replicon-replicating cell according to claim 7 in the presence of a test substance and detecting replication of a replicon RNA in the resulting culture.
10. A replicon-replicating cell created by introducing the replicon RNA according to claim 5 into isolated cells.
11. A replicon-replicating cell created by introducing the replicon RNA according to claim 6 into isolated cells.